Apogee Therapeutics, Inc.(APGE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
APGE Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Apogee Therapeutics, Inc. (APGE), a Healthcare sector company. APGE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of APGE by reported 13-F value include VR Adviser, BlackRock, HBK INVESTMENTS L P, based on the most recent SEC filings. APGE trades on the Nasdaq exchange and files with the SEC under CIK 1974640. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apogee Therapeutics, Inc. directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-40.5% YoYOperating Income
-31.7% YoYEPS (Diluted)
-27.9% YoYTotal Assets
+24.3% YoYOp. Cash Flow
-32.9% YoYFree Cash Flow
-35.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-255.8M -40.5% | $-182.1M -116.9% | $-84.0M -111.1% | $-39.8M |
| Operating Income | $-285.6M -31.7% | $-216.9M -133.2% | $-93.0M -202.7% | $-30.7M |
| EPS (Diluted) | $-4.22 -27.9% | $-3.30 +1.8% | $-3.36 +79.2% | $-16.16 |
| Total Assets | $937.1M +24.3% | $754.0M +87.8% | $401.4M +164.0% | $152.1M |
| Operating Cash Flow | $-227.4M -32.9% | $-171.2M -129.0% | $-74.8M -355.1% | $-16.4M |
| Free Cash Flow | $-232.6M -35.0% | $-172.3M -130.0% | $-74.9M | — |
Get alerted when APGE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Apogee Therapeutics, Inc. including:
Top Institutional Holders of APGE
VR Adviser, LLC
$1.1B8,493,321 shBlackRock, Inc.
$730.9M5,507,032 shHBK INVESTMENTS L P
$378.3M2,850,000 shVANGUARD CAPITAL MANAGEMENT LLC
$341.4M2,572,119 shFMR LLC
$330.9M2,493,137 shSTATE STREET CORP
$305.0M2,297,743 shDRIEHAUS CAPITAL MANAGEMENT LLC
$231.0M1,740,101 shGOLDMAN SACHS GROUP INC
$224.8M1,693,341 shBALYASNY ASSET MANAGEMENT L.P.
$221.0M1,665,102 shGLAZER CAPITAL, LLC
$217.8M1,641,042 sh
| Fund | Value | Shares |
|---|---|---|
| VR Adviser, LLC | $1.1B | 8,493,321 |
| BlackRock, Inc. | $730.9M | 5,507,032 |
| HBK INVESTMENTS L P | $378.3M | 2,850,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $341.4M | 2,572,119 |
| FMR LLC | $330.9M | 2,493,137 |
| STATE STREET CORP | $305.0M | 2,297,743 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $231.0M | 1,740,101 |
| GOLDMAN SACHS GROUP INC | $224.8M | 1,693,341 |
| BALYASNY ASSET MANAGEMENT L.P. | $221.0M | 1,665,102 |
| GLAZER CAPITAL, LLC | $217.8M | 1,641,042 |
More Healthcare Companies
View all Healthcare →Put APGE on your watchlist
Track score changes the day Apogee Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is APGE a good stock to buy?
13F Pro's AI-powered analysis of Apogee Therapeutics, Inc. (APGE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APGE are available on the APGE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. APGE is classified as a large company.
Which hedge funds own APGE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APGE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Apogee Therapeutics, Inc.'s investment landscape.